TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma

By afschroeder • September 9, 2025

Gross L, Mutisheva I, Hillen H, Robatel S, Wartenberg M, Ma F, Bäriswyl L, Lee DJ, Modlin RL, Z'graggen K, Schenk M. TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma. Mol Ther Oncol. 2025 Aug 14;33(3):201034. doi: 10.1016/j.omton.2025.201034. PMID: 40917508; PMCID: PMC12410479.

Tags: Dermatology, Harbor UCLA, immunotherapy, macrophage reprogramming, myeloid cells, PDAC, Publications, TREM-1 activation

Temporal CRAC channel blockade modulates the MYC-MXD axis to attenuate autoimmune inflammation

Wu B, Hasiakos S, Cokus S, Do M, Kaplan E, Pellegrini M, Sun Z, Kim RH, Srikanth S, Gwack Y. Temporal CRAC channel blockade modulates[...]

Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study

Armstrong A, Merola JF, Chughtai R, Fotiou K, Ngantcha M, Sabatino S, Megna M, Man X, Honma M, Carrascosa JM, Pinter A. Early and Maintained[...]

Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline

Smart K, Armstrong AW, Adler BL. Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline. Dermatitis. 2026 Sep[...]